NEW YORK (GenomeWeb) – Health technology company Tempus and Rush University Medical Center announced today their second collaboration geared toward accelerating research and treatment options for patients fighting cancer.
Tempus will facilitate the expansion and operations of Rush's research-focused biorepository, allowing the hospital to maintain and access tissue samples that Rush investigators can use to better understand and eventually treat cancer.
"Whether sequencing and analyzing patient data or building advanced patient derived biological models that can help determine patient response to treatment, we are committed to allowing top hospitals and researchers to access our technology platform in their battle against cancer" Tempus CEO Eric Lefkofsky said in a statement.
Rush and Tempus will also work together to develop 3D organoids, as well as other in vitro and in vivo models. The collaboration will allow Rush researchers to test how patients may respond to specific treatments, which is a crucial step toward more personalized cancer care.
Last fall, Tempus and Rush began their first collaboration involving sequencing and analysis services in order to advance Rush's personalized cancer treatment efforts.